SLEEP 2025: Analyzing High-Level, Late-Breaking Data

In this special report series from NeurologyLive, sleep specialists Eric Olson, MD, and Anita Shelgikar, MD, president-elect of the AASM, offer expert commentary on six late-breaking presentations from the 2025 SLEEP Annual Meeting in Seattle. The panel examines key findings in narcolepsy and hypersomnia, including new data on the cardiovascular safety and high-dose efficacy of low-sodium oxybate, real-world prescribing trends, and the role of social determinants of health in clinical outcomes. The discussion also explores investigational therapies such as TAK-861 and ALKS 2680, highlighting their mechanisms, study designs, and potential clinical implications. Together, these insights provide a timely update on the evolving treatment landscape for central disorders of hypersomnolence.